Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcR...

Full "IntellAsia: Resources" article